GAITHERSBURG, Md., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will present data from recent preclinical studies of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Nanoparticle Vaccine) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., September 5-9, 2014 at the Walter E. Washington Convention Center.
The presentation numbers, titles, dates and times are listed below:
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.